Rueda-Ochoa OL, et al. - In this secondary analysis of the Systolic Blood Pressure Intervention Trial (SPRINT), researchers assessed intensive hypertension treatment efficacy in relation to cumulative systolic blood pressure (SBP) and serious adverse events (SAEs). SPRINT was a randomized, controlled, open-label trial that was conducted at 102 US clinical sites, and included 9,068 participants with 128,139 repeated SBP measurements. Participants were randomized to receive either intensive (target SBP < 120 mmHg) or standard treatment (target SBP between 135 and 139 mmHg). Although intensive treatment reduced the risk for the primary SPRINT outcome (composite of myocardial infarction, other acute coronary syndromes, acute decompensated heart failure, stroke, and cardiovascular mortality) at the start of follow-up, its beneficial impact diminished following 3.4 years of follow-up in the total SPRINT population. Cumulative SBP and development of SAEs during follow-up might, therefore, offset the initial benefits observed with intensive hypertension treatment.